"The combination of hydroxychloroquine plus azithromycin was reserved for selected patients with severe COVID-19 and with minimal cardiac risk factors," the team wrote.
He said this might have skewed the results to make hydroxychloroquine look better than it really was.
"There's a little bit of loosey-goosiness here in all this,"